Shobha Rani Vootukuri, MD
Infectious Disease · Baton Rouge, LANPI 1215263009
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $290 and has fallen 73.5% since, to $77 in 2025.
Across 45 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$138
- Teva Pharmaceuticals USA, Inc.$118
- AbbVie$81
- Merck$69
- Shionogi Inc$58
- Amneal Pharmaceuticals LLC$56
- plus $361 from 14 others
What the payments were for
- Food & beverage$85297%
- Education$293%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $138 |
| Teva Pharmaceuticals USA, Inc. | 4 | $118 |
| AbbVie | 4 | $81 |
| Merck | 5 | $69 |
| Shionogi Inc | 2 | $58 |
| Amneal Pharmaceuticals LLC | 4 | $56 |
| Melinta Therapeutics, LLC | 2 | $48 |
| Biogen | 2 | $34 |
| Insmed, Inc. | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $28 |
| Seqirus USA Inc | 1 | $25 |
| Neurelis, Inc. | 1 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| Argenx US, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Tanabe Pharma America, Inc. | 1 | $16 |
How this compares
$881 in reported general payments places this provider in the 55th percentile of 105 infectious disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 30 | $26,512 |
| ErtapenemErtapenem Sodium | 23 | $14,201 |
| Vancomycin Hcl | 28 | $9,888 |
| CeftriaxoneCeftriaxone Sodium | 51 | $8,201 |
| Meropenem | 19 | $4,480 |
| Ampicillin Sodium | 19 | $4,065 |
| Doxycycline Hyclate | 101 | $2,804 |
| Cefazolin Sodium | 32 | $1,533 |
| Cefadroxil | 35 | $1,268 |
| Amikacin Sulfate | 13 | $921 |
| Amoxicillin | 34 | $456 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Baton Rouge
- Walter CampbellBaton Rouge$6K
- Waref AzmehBaton Rouge$2K
- Maria Reyes AngelesBaton Rouge$2K
- Breanna CampbellBaton Rouge$1K
- Patrick NjokuBaton Rouge$979
- Scott AndersonBaton Rouge$937
- Madeleine HeckBaton Rouge$611
- John NnadiBaton Rouge$491
- Hector Brunet RodriguezShreveport$592K
- Guillermo Padilla-PinedaShreveport$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.